当前位置: 首页 > 期刊 > 《中国医学创新》 > 2025年第16期
编号:2390763
益生菌制剂联合多奈哌齐在轻中度认知障碍伴衰弱患者中的临床疗效观察
http://www.100md.com 2025年8月9日 中国医学创新 2025年第16期
     Observationof the Clinical Efficacy of Probiotic Preparation Combined with Donepezil in Patients withMild-moderate Cognitive Impairment andFrailty/YU Yifeng,RUANWenjing,ZHOU Zhun. // Medical Innovation of China,2025,22(16): 022-026

    [Abstract]Objective:To observe the efficacy of probiotic preparation combined with Donepezil in patients with mild-moderatecognitive impairmentand frailty.Method: A totalof 8Opatients with mild-moderatecognitive impairment and frailtyAlzheimer'sdisease (AD) treated in Shangrao People's Hospital from January 2O22 to January 2024 were selected and divided into study group and control group according to random number table method, with 40 cases in each group.Both groups were given nutritional support,the control group was treated with Donepezil, and the study group was treated with probiotic preparation based on the control group.The clinical effcacy,the score of mini-mental state examination (MMSE),Barthel index,prealbumin (PA),transferin (TRF),albumin (ALB), interleukin-6 (IL-6),hypersensitive C reactive protein (hs-CRP)and serum neurofilament light chain protein (Nf-L) and neuron-specific enolase (NSE)levels were evaluated in both groups before treatment and 6 months after treatment. Result: After6 months of treatment ......

您现在查看是摘要页,全文长 12595 字符